Results 141 to 150 of about 128,640 (296)

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea

open access: yesObesity Science & Practice
Background and Aim Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists are well‐established therapies for obesity and type 2 diabetes mellitus (T2DM). Emerging evidence also suggests their potential role in managing obstructive sleep apnea (OSA).
Bei‐Bei Qian   +4 more
doaj   +1 more source

White Adipose Tissue Browning and Cross Talk With Metabolic Diseases and Tumors: From Molecular Mechanisms to Clinical Translation

open access: yesMed Research, EarlyView.
White adipose tissue undergoes browning under endogenous and exogenous stimuli, primarily regulated by core molecules such as PRDM16 and UCP1. It exhibits a double‐edged sword effect in metabolic diseases and tumors: while mitigating metabolic disease impacts and suppressing early‐stage tumors through nutritional competition, it may accelerate cachexia
Yingjiao Wang   +12 more
wiley   +1 more source

Diabetic Peripheral Neuropathy: Molecular Staging, Risk Factors, Therapeutics, and Emerging Trends

open access: yesMed Research, EarlyView.
The heterogeneous landscape of DPN can be unified through a tripartite pathogenic model encompassing progressive stages of metabolic dysregulation, chronic inflammation, and overt neuronal damage. Within this framework, six clinical subtypes were identified, namely, hyperglycemia‐driven, dyslipidemia‐driven, inflammation‐driven, dysvascularity‐driven ...
Xiaofeng Dai, Mingze Tang
wiley   +1 more source

Correlation Between Gut Microbiota, Metabolites, and Diabetic Complications: A Two‐Sample Mendelian Randomization Study

open access: yesMedicine Advances, EarlyView.
Fang et al. demonstrate a significant causal relationship among gut microbiota, gut metabolites, and diabetic complications, highlighting a biological link underlying mechanisms of diabetic vascular diseases. These findings provide important implications for future therapeutic strategy and risk prediction.
Jiaxi Fang   +6 more
wiley   +1 more source

The Expanding Landscape of Microbiota Medicine: Indications, Therapeutic Modalities, and the Path Towards Integrative Microbiome‐Targeting Healthcare

open access: yesMicrobiota Medicine Research, EarlyView.
ABSTRACT The growing recognition of the microbiome's role in human health has propelled the emergence of microbiota medicine—a new discipline integrating microbiology, multi‐omics, and clinical science. Advances in sequencing, data integration, and interventions such as fecal microbiota transplantation (FMT) have transitioned the field from ...
Min Dai   +6 more
wiley   +1 more source

Influence of dietary intake and eating patterns on reactive hypoglycemic events in patients postesophagectomy: A prospective observational study using continuous glucose monitoring

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Background Esophagectomy causes anatomical changes that can lead to rapid food transit and reactive hypoglycemia (RH). Patients are advised on eating patterns postesophagectomy to prevent RH, but its true incidence and the impact of dietary recommendations remain under‐researched.
Rachel O'Kelly   +9 more
wiley   +1 more source

A case report on the long‐term use of teduglutide in a pediatric patient with short bowel syndrome

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Short bowel syndrome (SBS) is the leading cause of intestinal failure, frequently necessitating long‐term parenteral nutrition (PN). Teduglutide (TED), a glucagon‐like peptide‐2 analog, has demonstrated efficacy in reducing PN dependence in both adults and children. However, long‐term data in pediatric populations remain limited.
Tsuyoshi Sakurai   +8 more
wiley   +1 more source

Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS‐1 phase 3 trial

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Background A randomized, double‐blind, placebo‐controlled trial was conducted to evaluate efficacy and safety of glepaglutide in patients who have short bowel syndrome with intestinal failure (SBS‐IF). At the end of the trial, exit interviews were conducted to explore participants' experiences and to assess the impact of the disease and ...
David F. Mercer   +5 more
wiley   +1 more source

GLP‐1 Receptor Agonists for Obstructive Sleep Apnea: An Otolaryngologist's Prescription?

open access: yes
The Laryngoscope, EarlyView.
Alina Zgardau   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy